

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: CB2 Insights Inc. (the "Issuer").

Trading Symbol: CBII

Number of Outstanding Listed Securities: 79,997,556

Date: October 3, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On September 3, 2019 the Issuer announced it was entering the Colombian market to advance medical cannabis research efforts within the country. The focus is to build Colombia's patient registry and grow the country's physician network using CB2's proprietary artificial intelligence-based Decision Support Tool and CB2's Sail, the industry's first Clinical Trial Data Management System. To achieve these goals, CB2

has appointed Dr. Paola Cubillos, MD, a prominent Colombian naturopathic and integrative medicine physician, as the Company's Medical Director in Colombia.

Dr. Cubillos was trained and has practiced in both Toronto, Canada and Colombia. Fusing both conventional and naturopathic treatments, she has spearheaded several medical cannabis research efforts at Clinica Las Americas, a highly recognized private hospital in Colombia that belongs to one of the largest healthcare networks in Latin America. Dr. Cubillos has been at the forefront of medical cannabis advancements and physician perception and education throughout Colombia and Latin America.

"There has been solid growth in positive physician perception throughout Colombia, but we are now at an inflection point where cultivators and manufacturers must embrace traditional research protocols to truly commercialize their products in a meaningful way," said Dr. Paola Cubillos, Medical Director, Colombia, CB2 Insights. "CB2 Insights has become the go-to name for cannabis-focused research programs in the US, Canada and the United Kingdom, and I'm excited to bring that experience to the Colombian market."

CB2's Colombian Opportunity

Colombia represents one of the world's most important emerging medical cannabis markets. Major local and international cultivators and product manufacturers have invested heavily in the Colombian market as of late, including: Canopy Growth, Aphria, Khiron, Medicine Man Technologies and PharmaCielo. Experts have estimated that Colombia could supply as much as two fifths of the world's cannabis in the future¹. CB2 Insights, by way of its new Medical Director, Dr. Cubillos will look to be the bridge between physician readiness and the substantial product development occurring within Colombia.

The Company will focus its efforts on supporting Licensed Producers, product manufacturers, pharmaceutical companies and other stakeholders in Colombia that require comprehensive research strategies to bring cannabis-based medicines to market. Traditional clinical research has often been a challenge for manufacturers due to regulatory restrictions and lack of clear guidelines to follow traditional product development frameworks, thus diminishing physicians' willingness to integrate medical cannabis products into traditional treatment plans.

In the immediate-term, the Company will work to build the patient registry within Colombia, grow the network of physicians ready to prescribe medical cannabis within their practice and support stakeholders in the complete management and execution of clinical trials; data which will help to generate safety and efficacy data for local regulatory agencies including INVIMA – Colombia's National Food and Drug Surveillance Institute. In addition, the Company will launch its proprietary Decision Support Platform to help provide point-of-care education and reference guidelines to physicians seeking to identify cannabis as a treatment option for their patients. CB2 Insights' tools will enable physicians to follow standardized protocols in assessing, determining and prescribing medical cannabis including the identification of patient-specific potential risk factors, drug-drug interactions, dosing guidelines and titration schedules.

On September 19 the Issuer announced that MyAccess Clinics ("MAC") had selected CB2 Insights' Electronic Data Capture (EDC) software to manage patient data within its growing number of medical clinics in the UK. MyAccess Clinics is a wholly-owned subsidiary of leading global medical cannabis company, Althea Group Holdings Ltd (ASX:AGH).

"The UK market continues to blossom at a rapid pace, and we are proud that our research and data technology assets continue to be sought to expedite growth in the market," said Prad Sekar, Chief Executive Officer, CB2 Insights. "MyAccess Clinics has an exceptional and comprehensive vision for its development in the UK's medical cannabis market and we are excited to be a part of that effort."

CB2 Insights' EDC software has been used throughout the US and Canada and uses standard healthcare protocols. The system is purpose-built for medical cannabis operations and takes into account the complexity of managing data related to multiple indications across a single patient base, comorbidity in certain patient profiles, past traditional therapies and multiple consumption methods and medicine within

¹ Source: Financial Times. [Colombia seeks to be a cut above on cannabis](#). July 20, 2019.

a single treatment plan. The system works to simplify data input and management while ensuring collection can ultimately be used to better understand the efficacy of cannabinoid therapy. This deployment will increase both the size and scope of the Company's data set.

Graham Woodward, MyAccess Clinics Clinical Director said "As a company, we are proud to be one of the first to service the emerging UK medical cannabis market. CB2 Insights' software will play an integral part in the administration of our clinics and will increase our ability to manage data, thereby improving our patient care."

Earlier this year, CB2 Insights announced that it had been selected as the exclusive research technology platform for UK-based Drug Science and its medical cannabis pilot program.

2. Provide a general overview and discussion of the activities of management.
None other than as described in 1 above.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
n/a
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
n/a
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
n/a
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
n/a
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
n/a
8. Describe the acquisition of new customers or loss of customers.
n/a

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
n/a
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
n/a
11. Report on any labour disputes and resolutions of those disputes if applicable.
n/a
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
n/a
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
n/a
14. Provide details of any securities issued and options or warrants granted.
n/a
15. Provide details of any loans to or by Related Persons.
n/a
16. Provide details of any changes in directors, officers or committee members.
n/a
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated October 3, 2019.

Kash Qureshi
Name of Director or Senior
Officer

"signed"
Signature
COO
Official Capacity

<i>Issuer Details</i> Name of Issuer CB2 Insights Inc.	For Month End September	Date of Report YY/MM/D 19/10/03
Issuer Address 5045 Orbitor Drive		
City/Province/Postal Code Mississauga, ON L4W 4Y4	Issuer Fax No. ()	Issuer Telephone No. (855) 874-4999
Contact Name Catherine Beckett	Contact Position Manager Corporate Affairs	Contact Telephone No. 416-642-1807